Sociedad Americana de Hirudoterapia

Neuroprotective effects of hirudin against cerebral ischemia-reperfusion injury via inhibition of CCL2-mediated ferroptosis and inflammatory pathways

Research article published in Brain Res Bull (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalLiao J et al. · Brain Res Bull, 2025

Abstract

Cerebral ischemia-reperfusion injury (CIRI) is a leading cause of neurological impairment in stroke, primarily correlated to oxidative stress, inflammation, and ferroptosis. This study investigates the neuroprotective effects of hirudin on CIRI, focusing on its role in modulating neuronal survival, oxidative stress, and ferroptosis markers through inhibition of CCL2. A middle cerebral artery occlusion (MCAO) model in mice and an oxygen-glucose deprivation/reoxygenation (OGD/R) model in HT22 cells were used to simulate ischemic conditions. Hirudin significantly improved neurological function and reduced cerebral edema and infarct size in the MCAO model. In vitro, hirudin enhanced neuronal viability and reduced apoptosis in OGD/R-stimulated cells. Integrative network pharmacology and transcriptomic analysis identified CCL2 as a potential target of hirudin. Hirudin treatment suppressed CCL2 expression, which in turn reduced the TLR4/NF-κB signaling activation, thereby mitigating ferroptosis and inflammatory responses in ischemic neurons. Overexpression of CCL2 partially reversed these protective effects, underscoring its role in ischemic injury. These findings suggest that hirudin alleviates CIRI by modulating CCL2 and preventing ferroptosis, offering insights into its potential as a therapeutic agent for ischemic conditions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsFerroptosisChemokine CCL2Reperfusion InjuryHirudinsMiceNeuroprotective AgentsMaleMice, Inbred C57BLSignal TransductionInfarction, Middle Cerebral ArteryBrain Ischemia

Resumen

Cerebral ischemia-reperfusion injury (CIRI) is a leading cause of neurological impairment in stroke, primarily correlated to oxidative stress, inflammation, and ferroptosis.

Por qué esto importa para la hirudoterapia

This study examined the neuroprotective effects of hirudin against cerebral ischemia-reperfusion injury (CIRI) using a mouse MCAO model and an OGD/R model in HT22 cells, focusing on hirudin's modulation of CCL2-mediated ferroptosis and inflammatory pathways. Hirudin improved neurological function, reduced cerebral edema and infarct size, enhanced neuronal viability, and reduced apoptosis, with network pharmacology and transcriptomic analysis identifying CCL2 as a target whose suppression reduced TLR4/NF-κB activation, ferroptosis, and inflammation; overexpression of CCL2 partially reversed protective effects. This is directly relevant to the ASH domain as it investigates therapeutic mechanisms of a leech-derived anticoagulant in ischemic stroke models. Caveat: This is a preclinical study using mouse and cell culture models, and the findings have not been validated in human subjects or clinical trials.

Citación

Neuroprotective effects of hirudin against cerebral ischemia-reperfusion injury via inhibition of CCL2-mediated ferroptosis and inflammatory pathways.

Liao J et al. · Brain Res Bull, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.